ArticleBMC urology2025
Clinical and imaging characteristics of classic angiomyolipoma with venous tumor thrombosis: a comparative analysis against renal cell carcinoma.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Computed Tomography of Neoplastic Infiltrating Renal Masses in Patients Without a Previous History of Cancer.Cancers · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo retrospectively analyze the clinical and imaging characteristics of classic angiomyolipoma (CAML) with venous tumor thrombus (VTT) and compare them with those of clear cell renal cell carcinoma (ccRCC).
methodsClinical data from six patients with renal CAML complicated by VTT and 18 with ccRCC complicated by VTT, treated at Peking University Third Hospital from April 2018 and June 2022, were retrospectively analyzed. All patients underwent preoperative ultrasound and contrast-enhanced CT. Clinical manifestations, imaging characteristics, surgical findings, and pathological data were collected, and patients were followed up.
resultsEnhanced CT showed renal sinus involvement in all CAML cases versus four ccRCC cases (p = 0.002). All primary CAML tumors had fatty components, compared to one ccRCC case (p < 0.001). Enhanced CT also revealed 7 VTTs with fatty components (6 in the CAML group) (p < 0.001). Thrombus lengths in the inferior vena cava (IVC) were 8.05 ± 2.22 cm for CAML and 5.29 ± 2.38 cm for ccRCC, with no significant difference (p = 0.610). The maximum/minimum anteroposterior VTT diameter ratios were 3.98 and 1.09, respectively (p < 0.001); coronal diameter ratios were 4.00 and 1.12, respectively (p < 0.001). Ultrasound revealed that, except for one Mayo Level 0 case, the involved IVC in the CAML group had continuous, intact walls with blood flow signals in the residual lumen, while in the ccRCC group, most VTTs had unclear boundaries and only one case showed blood flow signals in the residual lumen (p = 0.001). Intraoperative blood loss was significantly lower in CAML cases (p = 0.017). No CAML patient had VTT invading the venous wall, unlike 8 ccRCC patients (p = 0.016). All patients were followed for 21-74 months (median: 34.5 months, mean: 36.6 months). All were alive with normal renal function, and no tumor recurrence or metastasis was observed.
conclusionRenal CAML with VTT is characterized by three imaging features: the presence of fatty components, a unique geometric growth pattern, and the absence of venous wall invasion, potentially serving as valuable indicators for differentiating CAML from ccRCC lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.